We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Abbott Diagnostics

Abbott Diagnostics provides medical diagnostic instruments, tests, automation and informatics solutions, including cl... read more Featured Products: More products

Download Mobile App




C. Diff Carriers Are Source of Infections in Hospitals

By LabMedica International staff writers
Posted on 26 Dec 2019
Clostridioides difficile is a spore-forming, gram-positive anaerobic bacillus spread by fecal–oral transmission of spores, which remain viable for long periods of time ex vivo. More...
Although C. difficile carriers do not have diarrhea, they do shed spores that can contaminate environmental surfaces.

Annually, there are more than 400,000 cases and almost 30,000 deaths from C.difficile–associated diarrhea occur in the USA. Efforts to reduce the spread of C. difficile have focused on reducing transmission from patients with symptomatic C. difficile–associated diarrhea. Asymptomatic carriers may serve as a reservoir and spread C. difficile to those around them.

Medical scientists associated with the Montefiore Medical Center (The Bronx, NY, USA) performed a prospective cohort study on a sample of patients being admitted to a large university hospital between July 2017 and March 2018. The team tested 220 patients who showed no symptoms of C. difficile infection when they were admitted. Perirectal swabs (Copan Diagnostics, Murrieta, CA, USA) were completed within 24 hours of admission, and the patients were followed for six months.

Two testing methodologies were used for all specimens: C. difficile Quik Chek Complete (Abbott, Chicago, IL, USA) to test for glutamate dehydrogenase (GDH) and toxins A and B and XPert C. difficile/Epi (Cepheid, Sunnyvale, CA, USA) real-time polymerase chain reaction (PCR) assay that detects the toxin B gene. All specimens were also tested by toxigenic culture using spore-enriched specimens in cultures with selective chopped meat broth incubated for 48–72 hours followed by repeat GDH and toxin A/B testing.

The scientists reported that of the 220 subjects, 21 (9.6%) were C. difficile carriers, including 10.2% of the nursing facility residents and 7.7% of the community residents. Among the 21 C. difficile carriers, eight (38.1%) progressed to symptomatic C. difficile, but only four (2.0%) of the 199 non-carriers progressed to symptomatic C. difficile.

The authors concluded that asymptomatic carriers may represent a significant reservoir for transmission of C. difficile, and progression from asymptomatic carriage to symptomatic C. difficile infection (CDI) may account for a significant proportion of CDI that is classified as “healthcare-facility onset.” Therefore, identification of asymptomatic carriers could reduce the spread of C. difficile. Specific environmental, isolation, and stewardship strategies to prevent spread of C. difficile from carriers to uninfected patients as well as prevent progression to symptomatic CDI warrant further study.

Sarah Baron, MD, MS, an Assistant Professor of Medicine and lead author of the study, said, “It has generally been assumed that patients get the bacteria during their stay in the hospital. However, when we tested patients being admitted to the hospital, we found that many of them were carrying the bacteria that cause this diarrhea in their bodies already and often went on to develop the infection.” The study was published on December 11, 2019 in the journal Infection Control & Hospital Epidemiology.

Related Links:
Montefiore Medical Center
Copan Diagnostics
Abbott
Cepheid



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
Multichem ID-B
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.